This inventor holds 1 USPTO granted patent. Top assignees: Centre Hospitalier Régional Universitaire De Besançon, Etablissement Francais Du Sang, Institut National De La Sante Et De La Recherche Medicale. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3 
1 out of 29 
1 out of 14 
Years Active: 2026
Title: Fanny Angelot-delettre: Research and Patent Work
Introduction
Fanny Angelot-delettre is an inventor based in La Plaine Saint-Denis, France. Her patent work includes research on antibodies and engineered immune-cell therapies targeting CD123.
Latest Patents
Angelot-delettre is associated with 1 patent: “Anti-CD123 Antibodies, Anti-CD123 Chimeric Antigen Receptors and Anti-CD123 Chimeric Antigen Receptor T Cells.” The invention concerns CD123-targeting antibodies and chimeric antigen receptor approaches involving T cells.
Career Highlights
The organizations listed in connection with Angelot-delettre are Université de Franche-Comté and the French National Institute of Health and Medical Research (INSERM). Her patent reflects work in biomedical research and immunotherapy.
Collaborations
Her listed collaborators include Francine Garnache-Ottou and Christophe Ferrand. Their shared work is associated with research into CD123-targeted therapeutic technologies.
Conclusion
Fanny Angelot-delettre’s recorded patent work highlights her contribution to research on CD123-targeted antibodies and CAR T-cell approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile